本文選題：造血干細胞移植 + 間充質(zhì)干細胞��； 參考：《中國實驗血液學(xué)雜志》2017年04期

【摘要】：目的:探討單倍體相合造血干細胞移植(haploidentical-HSCT,hi-HSCT)聯(lián)合骨髓間充質(zhì)干細胞(BMM SC)輸注治療兒童重型再生障礙性貧血(SAA)的療效。方法:回顧性分析25例行hi-HSCT聯(lián)合BM-M SC輸注治療兒童SAA的臨床資料,觀察移植后造血恢復(fù)及移植相關(guān)并發(fā)癥。結(jié)果:25例患兒中性粒細胞均植入,植入中位時間為12(11-22)d,其中23例血小板植入,中位植入時間為21(11-130)d。16例發(fā)生急性移植物抗宿主病(a GVHD),其中11例為Ⅰ度,5例為Ⅱ-Ⅳ度,1例在移植后115 d死于累及皮膚、腸道及肝臟的Ⅳ度a GVHD,5例發(fā)生慢性GVHD(c GVHD),均為局限性c GVHD。發(fā)生CMV血癥的有23例,無1例進展為CMV病。23例患兒發(fā)生EBV血癥,且其中有3例發(fā)生移植后淋巴增殖性疾病,經(jīng)利妥昔單抗治療后均治愈。出血性膀胱炎發(fā)生9例,僅1例為Ⅲ度。22例發(fā)生感染,其中10例為肺部感染,4例為肝臟感染。1例發(fā)生格林-巴利綜合征。1例出現(xiàn)自身免疫性溶血性貧血。22例患兒存活且脫離輸血,中位隨訪時間為14(3-27)個月。結(jié)論:hi-HSCT聯(lián)合BM-MSC輸注治療兒童SAA是安全、可行的。
[Abstract]:Objective: to investigate the efficacy of haploidentical-HSCThi-HSCT combined with bone marrow mesenchymal stem cell (BMM) in the treatment of severe aplastic anemia in children. Methods: the clinical data of 25 cases of children SAA treated with hi-HSCT combined with BM-M SC infusion were retrospectively analyzed and the hematopoietic recovery and transplantation related complications were observed. Results neutrophilic granulocytes were implanted in 25 cases of children. The median time of implantation was 12 ~ 11 ~ 22 d, of which 23 cases were implanted with platelets. The median implantation time was: acute graft-versus-host disease (21(11-130)d.16) occurred in 5 patients with acute graft-versus-host disease (GVHD). Among them, 11 cases were grade 鈪，

本文編號：2016336